CN101553251B - 针对4种登革热血清型的免疫方法 - Google Patents

针对4种登革热血清型的免疫方法 Download PDF

Info

Publication number
CN101553251B
CN101553251B CN2007800444299A CN200780044429A CN101553251B CN 101553251 B CN101553251 B CN 101553251B CN 2007800444299 A CN2007800444299 A CN 2007800444299A CN 200780044429 A CN200780044429 A CN 200780044429A CN 101553251 B CN101553251 B CN 101553251B
Authority
CN
China
Prior art keywords
den
dengue
virus
vaccine
serotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800444299A
Other languages
English (en)
Chinese (zh)
Other versions
CN101553251A (zh
Inventor
B·盖伊
R·福拉特
J·兰
V·巴班
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of CN101553251A publication Critical patent/CN101553251A/zh
Application granted granted Critical
Publication of CN101553251B publication Critical patent/CN101553251B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2007800444299A 2006-10-04 2007-10-02 针对4种登革热血清型的免疫方法 Expired - Fee Related CN101553251B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0608660A FR2906724B1 (fr) 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue.
FR0608660 2006-10-04
PCT/FR2007/052054 WO2008047023A2 (fr) 2006-10-04 2007-10-02 Methode d'immunisation contre les 4 serotypes de la dengue

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310128837XA Division CN103285386A (zh) 2006-10-04 2007-10-02 针对4种登革热血清型的免疫方法

Publications (2)

Publication Number Publication Date
CN101553251A CN101553251A (zh) 2009-10-07
CN101553251B true CN101553251B (zh) 2013-05-22

Family

ID=38222583

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2007800444299A Expired - Fee Related CN101553251B (zh) 2006-10-04 2007-10-02 针对4种登革热血清型的免疫方法
CN201310128837XA Pending CN103285386A (zh) 2006-10-04 2007-10-02 针对4种登革热血清型的免疫方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310128837XA Pending CN103285386A (zh) 2006-10-04 2007-10-02 针对4种登革热血清型的免疫方法

Country Status (15)

Country Link
US (2) US7718358B2 (https=)
EP (3) EP2526965A1 (https=)
JP (1) JP5269796B2 (https=)
KR (1) KR20090064593A (https=)
CN (2) CN101553251B (https=)
AR (1) AR063057A1 (https=)
AU (1) AU2007311792B2 (https=)
BR (1) BRPI0719849A2 (https=)
CA (1) CA2663885A1 (https=)
FR (1) FR2906724B1 (https=)
IL (2) IL197768A0 (https=)
MX (1) MX2009003417A (https=)
TW (2) TWI406673B (https=)
WO (1) WO2008047023A2 (https=)
ZA (1) ZA200901816B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080193477A1 (en) * 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
ES2615390T3 (es) 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
NZ597000A (en) * 2009-06-01 2014-07-25 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
EP2473624B1 (en) 2009-08-31 2019-05-01 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) * 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
WO2011119628A2 (en) 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
SG195115A1 (en) * 2011-06-29 2013-12-30 Immunotope Inc Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection
NZ630831A (en) * 2012-06-10 2019-02-22 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
US8895028B2 (en) * 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
KR20150036593A (ko) 2012-07-24 2015-04-07 사노피 파스퇴르 뎅기열 바이러스 감염 예방용 백신 조성물
MX381497B (es) 2012-07-24 2025-03-12 Sanofi Pasteur Composiciones vacuna.
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
JP2016504315A (ja) * 2012-12-14 2016-02-12 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 三価デングウイルス製剤に関する組成物、投与方法および使用
BR112015031226A2 (pt) 2013-06-21 2017-08-29 Merck Sharp & Dohme Composição de vacina, e, uso da composição de vacina
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
EP3236997B1 (en) 2014-12-22 2024-05-29 Merck Sharp & Dohme LLC Dengue virus vaccine compositions and methods of use thereof
BR112017028212A2 (pt) 2015-07-03 2018-09-11 Sanofi Pasteur vacinação concomitante contra dengue e febre amarela
EP3382012A4 (en) * 2015-11-27 2019-07-03 KM Biologics Co., Ltd. LIVING VIRUS WITH A BANK OF ATTENUATED TREES OF DENGUEVIRUS AND DENGUE VACCINE THEREFORE AS ANTIGENE
SG11202002933TA (en) 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
WO2020051334A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
MX2022001742A (es) 2019-08-16 2022-04-07 Takeda Vaccines Inc Metodos para prevenir el dengue y la hepatitis a.
EP4110381A1 (en) 2020-02-27 2023-01-04 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
EP4519847A1 (en) 2022-05-04 2025-03-12 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
EP4375381B1 (en) 2022-11-18 2026-02-25 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated dengue virus having a nucleotide sequence comprising at least one attenuation locus in a formulation
CN120529951A (zh) 2022-11-29 2025-08-22 武田疫苗股份有限公司 大规模黄病毒疫苗生产和制造
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057910A1 (en) * 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
EP1159968A1 (fr) * 2000-05-30 2001-12-05 Mahidol University Souches atténuées du virus de la Dengue et leur utilisation dans une composition vaccinale
WO2003101397A2 (en) * 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6093296A (en) 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
HU228705B1 (en) 1997-02-28 2013-05-28 Univ St Louis Chimeric flavivirus vaccines
AU4224499A (en) 1998-05-29 1999-12-13 Epimmune, Inc. Identification of broadly reactive dr restricted epitopes
AU4179200A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-1 virus vaccine
JP2002540168A (ja) * 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 多価デングウイルスワクチン
JP2002540166A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱３型ウイルスワクチン
US6511667B1 (en) 1999-03-26 2003-01-28 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-2 virus vaccine
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP3000477A1 (en) 2000-02-16 2016-03-30 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Avirulent, immunogenic flavivirus chimeras
EP1159969A1 (fr) 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
DK2290109T3 (da) 2001-05-22 2014-11-10 Us Gov Health & Human Serv Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira
KR20040004642A (ko) 2001-05-23 2004-01-13 덴드레온 샌 디에고 엘엘씨 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도
WO2002102828A2 (en) 2001-06-01 2002-12-27 Acambis, Inc. Chimeric flavivirus vectors
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
KR101194818B1 (ko) * 2002-01-15 2012-10-25 사노피 파스테르 바이오로직스, 엘엘씨 플라비바이러스 백신
DE602004027902D1 (de) 2003-03-24 2010-08-12 Scripps Research Inst Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
CN101238144B (zh) * 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
US20080193477A1 (en) * 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057910A1 (en) * 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
EP1159968A1 (fr) * 2000-05-30 2001-12-05 Mahidol University Souches atténuées du virus de la Dengue et leur utilisation dans une composition vaccinale
WO2003101397A2 (en) * 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine";ROTHMAN A L ET AL:;《VACCINE》;20010914;第19卷(第32期);4694-4699 *
"Live attenuated tetravalent dengue vaccine";BHAMARAPRAVATI N ET AL:;《VACCINE》;20000331;第18卷;44-47 *
"Sculpting the immunological response to dengue fever by polytopic vaccination";ZHOU ET AL:;《VACCINE》;20060324;第24卷(第14期);参见全文 *
"STUDIES ON THE IMMUNIZATION OF MONKEYS AGAINST DENGUE. II. PROTECTION FOLLOWING INOCULATION OF COMBINATIONS OF VIRUSES";HALSTEAD S B ET AL:;《AMERICAN JOURNAL OF TROPICAL MEDICINE & HYGIENE》;19730531;第22卷(第3期);375-381 *

Also Published As

Publication number Publication date
AU2007311792A1 (en) 2008-04-24
FR2906724B1 (fr) 2009-03-20
AU2007311792B2 (en) 2013-05-02
JP2010505801A (ja) 2010-02-25
ZA200901816B (en) 2010-06-30
US20080085288A1 (en) 2008-04-10
FR2906724A1 (fr) 2008-04-11
CN101553251A (zh) 2009-10-07
WO2008047023A2 (fr) 2008-04-24
IL224572A (en) 2014-06-30
US7718358B2 (en) 2010-05-18
TW200826959A (en) 2008-07-01
CA2663885A1 (en) 2008-04-24
EP2526964A1 (fr) 2012-11-28
WO2008047023A3 (fr) 2008-10-23
BRPI0719849A2 (pt) 2014-04-29
TW201336508A (zh) 2013-09-16
EP2077857B1 (fr) 2013-11-20
TWI406673B (zh) 2013-09-01
EP2526965A1 (fr) 2012-11-28
JP5269796B2 (ja) 2013-08-21
CN103285386A (zh) 2013-09-11
IL197768A0 (en) 2011-08-01
EP2077857A2 (fr) 2009-07-15
US20100270202A1 (en) 2010-10-28
AR063057A1 (es) 2008-12-23
KR20090064593A (ko) 2009-06-19
MX2009003417A (es) 2009-04-09

Similar Documents

Publication Publication Date Title
CN101553251B (zh) 针对4种登革热血清型的免疫方法
CN101489585B (zh) 针对登革病毒四种血清型的免疫接种方法
CN101541344A (zh) 针对4种登革热血清型的免疫方法
CN101238209B (zh) 登革血清型2减毒株
CN101238144A (zh) 登革血清型1减毒株
JPWO2006068307A1 (ja) 弱毒日本脳炎ウイルスの遺伝子をバックボーンとして有する弱毒キメラフラビウイルス

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130522

Termination date: 20161002